开发4'-化的核酸原药,以提高耐受性
Austin T Ryan1, Jean-Marc I A Lawrence1, Brett Virgin-Downey1
1Emory Institute for Drug Development (EIDD), Emory University, Atlanta, GA, 30322, USA.
European journal of medicinal chemistry
|February 25, 2026
概括
研究人员开发了一种新的前药物,EIDD-3639,由4'-尿素 (4'-FlU) 衍生,以提高口服抗病毒疗效和耐受性. 这种优化的抗病毒药物在治疗流感和其他病毒感染方面表现有前途,并减少了副作用.
科学领域:
- 开发抗病毒药物开发工作.
- 药品化学 药品化学 是一个
- 病毒学 病毒学
背景情况:
- 4'-尿素 (4'-FlU;EIDD-2749) 是一种口服有效的抗病毒药物,用于抗击流感,RSV和奇孔古尼亚病毒.
- 较高剂量的4'-FlU在小鼠中引起胃肠道不良影响和体重减轻,与肠道快速转化为活性三酸盐形式有关.
- 需要一种具有更好的耐受性和持续有效性的4'-FlU的前药衍生物.
研究的目的:
- 合成和评估4'-FlU的单酸原药,以提高耐受性和保持抗病毒功效.
- 为了确定一种具有减少胃肠道暴露于活性三酸盐形式的前药物.
- 为最有前途的候选人开发一个可扩展的合成.
主要方法:
- 在小鼠中合成和评估15种单酸原药的耐受性和抗A型 (H1N1) 流感的疗效.
- 对有希望的前药物进行组织分布研究,以测量活性三酸盐的暴露.
- 二聚体的分辨率和开发一种立体选择性合成路径.
主要成果:
- 作为4'-FlU的前药物,EIDD-2838,表现出更好的耐受性和疗效.
- EIDD-2838显示组织中的活性三酸盐暴露减少,包括肠道的4倍减少.
- PS二聚体,EIDD-3639,在低剂量 (2毫克/公斤) 时对H1N1保持有效性,并开发出可扩展的合成.
结论:
- EIDD-3639,EIDD-2838的特定二聚体体,代表了4'-尿素的优化前药物,具有更好的耐受性和保留的抗病毒活性.
- 开发EIDD-3639为治疗流感和潜在的其他病毒感染提供了一个有希望的治疗候选者.
- 一种立体选择性合成途径使EIDD-3639的大规模生产成为可能,用于进一步的临床开发.
相关概念视频
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
54
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
54
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
42
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
42
Prodrugs
4.5K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
Prodrugs help overcome...
4.5K
Modified-Release Drug Delivery Systems: Site-Targeted
51
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
51
Biosynthesis of Nucleic Acids
1.3K
Nucleic acid biosynthesis is a fundamental biochemical process that produces the purine and pyrimidine nucleotides essential for DNA and RNA synthesis. This pathway maintains a balanced nucleotide pool, preventing imbalances that could jeopardize genetic integrity and cellular function. Given the crucial role of nucleotides, their synthesis is tightly regulated to ensure proper cellular homeostasis.Purine BiosynthesisThe biosynthesis of purine nucleotides begins with ribose-5-phosphate, a...
1.3K
Pharmacokinetics in Pediatric Patients: Drug Excretion
336
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
336


